Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Orion Corporation, Orionintie 1, FI-02200 Espoo, Finland
Sandrena 0.5 mg gel.
| Pharmaceutical Form |
|---|
|
Gel, single-dose container. Smooth, opalescent gel. |
Estradiol hemihydrate corresponding to 0.5 mg estradiol per single-dose container.
Excipient with known effect: propylene glycol.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Estradiol |
Estradiol, is chemically and biologically identical to endogenous human estradiol. It substitutes for the loss of oestrogen production in menopausal women, and alleviates menopausal symptoms. Oestrogens prevent bone loss following menopause or ovariectomy. |
| List of Excipients |
|---|
|
Carbomer 974P |
Single-dose aluminium foil container (PET/Aluminium/PE) supplied in packages containing 28 or 91 single-dose containers. Not all pack sizes may be marketed.
Orion Corporation, Orionintie 1, FI-02200 Espoo, Finland
PL 27925/0015
Date of first authorisation: 19 November 1996
Date of latest renewal: 31 March 2010
| Drug | Countries | |
|---|---|---|
| SANDRENA | Australia, Brazil, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
